Trials / Completed
CompletedNCT00355082
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 226 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
Detailed description
The study consists of a Treatment phase, where efficacy is determined and a Continuation phase for extended safety information. The Continuation phase is open to all Treatment phase participants and those who did not qualify for treatment because of an insufficient number of seizures during the Baseline phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lamotrigine, 300 mg/day | 300 mg/day |
| DRUG | lamotrigine, 250 mg/day | 250 mg/day |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2006-07-21
- Last updated
- 2017-01-02
- Results posted
- 2009-11-25
Locations
103 sites across 8 countries: United States, Argentina, Chile, Costa Rica, Puerto Rico, Russia, South Korea, Ukraine
Source: ClinicalTrials.gov record NCT00355082. Inclusion in this directory is not an endorsement.